On June 26, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly^™), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

A primary care approach to combatting compassion fatigue in oncology nurses increases nurses’ mental well-being and organizational skills, a team of oncology nurses reported during a poster presentation at the 49th Annual ONS Congress^® in April 2024. Additionally, the intervention improves patient satisfaction with nursing interactions and care, they said.

Individuals born after 1965 have a 17% higher risk of developing accelerated aging compared to those born from 1950–1954, researchers reported at the American Association for Cancer Research Annual Meeting 2024. They demonstrated an association between accelerated aging and an increased risk for several types of early-onset solid tumors.

On February 16, 2024, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte cancer therapy for metastatic melanoma, lifileucel (Amtagvi™). Patients in the drug’s clinical trial experienced a significant decrease in tumor burden, and the median overall survival was 17.4 months.

More than 85% of oncology healthcare professionals say that they need to be able to explain clinical use of artificial intelligence (AI) to their patients, but less than half report being familiar with AI in health care or receiving education on the technology, researchers reported in JAMA Network Open. In response, the National Cancer Institute’s (NCI’s) Center for Biomedical Informatics and Information Technology created a top-5 tip sheet for clinicians and researchers to use when evaluating AI tools for health care.

Of the more than 20 million new cancer cases diagnosed globally in 2022, nearly half occurred in Asia—where an even higher majority of the 9.7 million deaths were also reported, according to the International Agency for Research on Cancer and American Cancer Society’s April 2024 estimates.

On June 21, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati^®) plus cetuximab for adults with KRAS G12C-variant locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

By representing perspectives from the entire cancer care team, collaboration with interprofessional colleagues is one way for oncology nurses to influence the delivery of high-quality patient care.

Confounding researchers and clinicians alike, colorectal cancer rates are dramatically increasing among younger populations. In the latest study results published in Gastroentrology, researchers quantified the drastic shift of colorectal cancer diagnoses in various young groups aged 10–24 years.

The journey from cancer diagnosis to treatment with hematopoietic stem cell transplantation (HSCT) is a complex, costly, and multifaceted process influenced by various factors that shape the course of patient care. HSCT is particularly susceptible to racial, socioeconomic, and geographic disparities in access and outcomes, given its specialized nature and limited availability in just about 200 U.S. cancer centers.